Evidence map›Paper›PMID 22664072›Full record

ArticleCurrent drug targets2012

Bacterial cell wall compounds as promising targets of antimicrobial agents I. Antimicrobial peptides and lipopolyamines.

Guillermo Martínez de Tejada, Susana Sánchez-Gómez, Iosu Rázquin-Olazaran, Ina Kowalski, Yani Kaconis, Lena Heinbockel, Jörg Andrä, Tobias Schürholz, Mathias Hornef, Aline Dupont and 5 more

Open access · greenAbstract read
In one paragraph

Article in Current drug targets, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Antioxidant and antibacterial activities of the rhizome extract ofJournal of advanced veterinary and animal research · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Interest of Homodialkyl Neamine Derivatives against ResistantInternational journal of molecular sciences · 2021
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 5 countries.

Guillermo Martínez de TejadaUniversity of Navarra, Dept. of Microbiology, Irunlarrea 1, E-31008 Pamplona, Spain.
Susana Sánchez-Gómez
Iosu Rázquin-Olazaran
Ina Kowalski
Yani Kaconis
Lena Heinbockel
Jörg Andrä
Tobias Schürholz
Mathias Hornef
Aline Dupont
Patrick Garidel
Karl Lohner
Thomas Gutsmann
Sunil A David
Klaus Brandenburg
Research Center Borstel - Leibniz Lung Center · DEMedizinische Hochschule Hannover · DERWTH Aachen University · DEUniversidad de Navarra · ESAustrian Academy of Sciences · ATLuther University · KRUniversity of Kansas · US

Funding

Preclinical development of DS-96, a novel alkylpolyamine endotoxin squestrantU01AI077947 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI DAVID, SUNIL A · 2008 to 2012
$1.8M
Gram-Negative Sepsis: Pharmacophore-Based TherapeuticsU01AI056476 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI DAVID, SUNIL ABRAHAM · 2003 to 2007
$1.6M
Hydrophobic Polyamine Amides as Anti-Endotoxin AgentsU01AI054785 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI DAVID, SUNIL ABRAHAM · 2003 to 2007
$1.3M
NIAID NIH HHS 5U01AI054785NIAID NIH HHS 5U01AI056476NIAID NIH HHS 5U01AI077947NIAID NIH HHS U01 AI054785NIAID NIH HHS U01 AI056476NIAID NIH HHS U01 AI077947
6 · The paper itself

Abstract

The first barrier that an antimicrobial agent must overcome when interacting with its target is the microbial cell wall. In the case of Gram-negative bacteria, additional to the cytoplasmic membrane and the peptidoglycan layer, an outer membrane (OM) is the outermost barrier. The OM has an asymmetric distribution of the lipids with phospholipids and lipopolysaccharide (LPS) located in the inner and outer leaflets, respectively. In contrast, Gram-positive bacteria lack OM and possess a much thicker peptidoglycan layer compared to their Gram-negative counterparts. An additional class of amphiphiles exists in Gram-positives, the lipoteichoic acids (LTA), which may represent important structural components. These long molecules cross-bridge the entire cell envelope with their lipid component inserting into the outer leaflet of the cytoplasmic membrane and the teichoic acid portion penetrating into the peptidoglycan layer. Furthermore, both classes of bacteria have other important amphiphiles, such as lipoproteins, whose importance has become evident only recently. It is not known yet whether any of these amphiphilic components are able to stimulate the immune system under physiological conditions as constituents of intact bacteria. However, all of them have a very high pro-inflammatory activity when released from the cell. Such a release may take place through the interaction with the immune system, or with antibiotics (particularly with those targeting cell wall components), or simply by the bacterial division. Therefore, a given antimicrobial agent must ideally have a double character, namely, it must overcome the bacterial cell wall barrier, without inducing the liberation of the pro-inflammatory amphiphiles. Here, new data are presented which describe the development and use of membrane-active antimicrobial agents, in particular antimicrobial peptides (AMPs) and lipopolyamines. In this way, essential progress was achieved, in particular with respect to the inhibition of deleterious consequences of bacterial infections such as severe sepsis and septic shock.

Indexed as

Amino Acid SequenceAnti-Infective AgentsBacteriaBacterial ProteinsCell WallMolecular Sequence DataPolyaminesAnti-Infective AgentsBacterial ProteinsPolyamines

Identifiers

PMID22664072
PMCPMC3694180
OpenAlexW2119306425

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.